Among the BMPs tested, BMP6 emerged as a potent regulator that is capable of restoring bone formation, inhibiting RANKL-induced osteoclastogenesis, and attenuating the tumor-supportive phenotype of MSCs, supporting its further exploration as a potential therapeutic strategy for multiple myeloma and its associated bone disease. The gene discussed is BMP6; the disease is plasma cell myeloma.